Gregory A. Morris

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Gregory Morris is a partner at O’Melveny. Armed with more than 20 years of legal experience and a Ph.D. in Organic Chemistry from Northwestern University, Gregory’s practice focuses on pharmaceutical, biotechnology, and medical device patent litigation. He represents the industry's most sophisticated companies on the brand-side in Hatch-Waxman litigation and regularly litigates inter partes review (IPR) proceedings before the US Patent & Trademark Office (USPTO).

Lauded as “one of the very best IP strategists,” clients note his “analytical ability — when he's faced with an issue he looks into it analytically from the outset.” Gregory is considered to be “a great communicator who really digs into the science and explains things in layman's terms”(Chambers USA). Gregory co-led a team of attorneys, for example, in the first-ever successful defense of an Orange Book-listed patent in an IPR review.

Among other accolades, Gregory is recognized in Chambers USA. IAM Patent 1000 recognized Gregory among the “World’s Leading Patent Practitioners” each year since 2020. He was recognized in the Crain’s Chicago Business 2019 list of “Notable Gen X Leaders in Law.” He has been named a Patent Star by Managing IP each year since 2016.  And he has been recognized as a Life Sciences Star by LMG Life Sciences each year since 2017. Gregory has also been quoted extensively in the media and writes and lectures widely on Hatch-Waxman litigation, biologics, and the PTAB.

Honors & Awards

  • Chambers USA: America's Leading Lawyers, 2021-2022
  • Managing Intellectual Property IP STARS, Recognized as a Patent Star, 2016-2022
  • IAM Patent 1000: The World’s Leading Patent Professionals, 2020-2021
  • Crain’s Chicago Business Notable Gen X Leaders in Law, 2019
  • LMG Life Sciences, Life Sciences Star, 2017-2021

Admissions

Bar Admissions

  • Illinois
  • New York
  • District of Columbia

Court Admissions

  • US Court of Appeals, Federal Circuit
  • US District Court, Eastern and Southern Districts of New York

Registered to Practice

  • US Patent & Trademark Office (USPTO)

Education

  • Fordham University School of Law, J.D., 2004: Associate Editor, Fordham Intellectual Property Media & Entertainment Law Journal
  • Northwestern University, Ph.D., Organic Chemistry, 2001
  • University of Michigan, B.A., English Literature

Professional Activities

Member

  • New Jersey Intellectual Property Owners Association
  • New York Intellectual Property Law Association
  • The Richard Linn American Inn of Court

Recent Speaking Engagements

  • Speaker, “Skinny Labeling: The Future of Carveouts and Analyzing the Influence of GSK v. Teva on Competition,” 8th Annual Paragraph IV Disputes Master Symposium, American Conference Institute (ACI) (November 2022)
  • Speaker, “Challenging Patents on Reference Drugs: Litigation Strategies for IPR Practice,” 13th Summit on Biosimilars & Innovator Biologics, American Conference Institute (ACI) (June 2022)
  • Moderator, “View from the Bench; The Federal Judges Speak on Paragraph IV Litigation, 17th Annual Paragraph IV Disputes,” American Conference Institute (ACI) (April 2022)
  • Speaker, “Latest Trends and Strategic Considerations for Biotech Patent Challenges at the PTAB, Annual PTAB Webinar Series,” New Jersey Intellectual Property Law Associate (NJIPLA) (February 2022)
  • Lead counsel for a pharmaceutical company in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug. Obtained consent judgments with injunctions against all defendants. (D. Del.) (Jan. 2020)
  • Represented a multinational pharmaceutical company and a conglomerate corporation in patent infringement litigation filed by a US-based global manufacturer relating to the pharmaceutical company’s prescription asthma product. Achieved a complete victory whereby the asserted patents were invalidated in parallel IPRs and the complaint was dismissed with prejudice. (PTAB) (Nov. 2019) (N.D. Ill.)(Jan. 2020)
  • Lead counsel for a pharmaceutical company in IPR proceeding where an opposing pharmaceutical company challenged client’s patent related to peptide therapeutics for the treatment of gastrointestinal disorders obtaining an order terminating the proceedings. (PTAB) (Nov. 2018)
  • Co-lead counsel for a multinational pharmaceutical company in IPR action against a Canadian pharmaceutical company who was seeking to challenge a patent protecting client’s prescription product. Obtained a win whereby the institution of the IPR proceeding was denied. (PTAB) (Oct. 2015)
  • Represented a Swiss pharmaceutical company and a biopharmaceutical company in parallel IPRs and Hatch-Waxman patent infringement litigation to protect clients’ prescription rosacea drug. Co-led team that obtained IPR win after final written decision that was the first-ever successful defense of an Orange Book-listed patent in an IPR review. Obtained consent judgments with injunctions against all defendants. (PTAB) (D. Del.)
  • Represented a global healthcare company in Hatch-Waxman patent infringement litigation to protect client’s prescription digestive drug. Obtained a bench trial verdict at the close of evidence finding infringement and upholding the validity of the patents. Obtained consent judgments with injunctions against all defendants. (D. Del.)
  • Represented an American pharmaceutical company in patent infringement litigation brought by a biopharmaceutical company involving client's humanized antibody drug, obtaining a dismissal of all claims. (D. Del.)
  • Represented a pharmaceutical company and a Danish international pharmaceutical company in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug. Obtained consent judgments with injunctions against all defendants after bench trial. (D. Del.)